B Braun Medical Company Profile
What is the competitive landscape for B BRAUN MEDICAL
B BRAUN MEDICAL has sixteen approved drugs.
There are three US patents protecting B BRAUN MEDICAL drugs.
Summary for B Braun Medical
| US Patents: | 3 |
| Tradenames: | 16 |
| Ingredients: | 15 |
| NDAs: | 16 |
Drugs and US Patents for B Braun Medical
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun Medical | ACETAMINOPHEN | acetaminophen | SOLUTION;INTRAVENOUS | 204957-001 | Feb 18, 2021 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | BUPIVACAINE HYDROCHLORIDE | bupivacaine hydrochloride | INJECTABLE;SPINAL | 209087-001 | Apr 2, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | meropenem | POWDER;INTRAVENOUS | 202106-002 | Apr 30, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| B Braun Medical | LEVETIRACETAM IN SODIUM CHLORIDE | levetiracetam | INJECTABLE;INTRAVENOUS | 209705-003 | Feb 27, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | LEVETIRACETAM IN SODIUM CHLORIDE | levetiracetam | INJECTABLE;INTRAVENOUS | 209705-002 | Feb 27, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | HEPARIN SODIUM | heparin sodium | INJECTABLE;INJECTION | 208827-001 | Nov 19, 2018 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| B Braun Medical | TROMETHAMINE | tromethamine | SOLUTION;INJECTION | 211558-001 | Dec 9, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for B Braun Medical
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| B Braun Medical | CLOROTEKAL | chloroprocaine hydrochloride | SOLUTION;INTRATHECAL | 208791-001 | Sep 26, 2017 | 8,969,412 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for B Braun Medical Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2621015 | ⤷ Start Trial |
| New Zealand | 709631 | ⤷ Start Trial |
| Philippines | 12015501313 | ⤷ Start Trial |
| South Korea | 102162587 | ⤷ Start Trial |
| Denmark | 1931304 | ⤷ Start Trial |
| Malaysia | 180957 | ⤷ Start Trial |
| Taiwan | 201412317 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for B Braun Medical Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2365988 | CA 2018 00006 | Denmark | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| 3412676 | 202040020 | Slovenia | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF VABORBACTAM AND/OR ITS SALT AND/OR ITS HYDRATE AND MEROPENEM AND/OR ITS SALT AND/OR ITS HYDRATE, MAINLY MEROPENEM TRIHYDRATE; NATIONAL AUTHORISATION NUMBER: EU/1/18/1334/001; DATE OF NATIONAL AUTHORISATION: 20181120; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2957286 | 6/2019 | Austria | ⤷ Start Trial | PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721 |
| 2603514 | 19C1021 | France | ⤷ Start Trial | PRODUCT NAME: COMBINAISON DE VABORBACTAME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, ET DE MEROPENEME, ET/OU D'UN SEL ET/OU D'UN HYDRATE DE CELUI-CI, EN PARTICULIER DE MEROPENEME TRIHYDRATE; REGISTRATION NO/DATE: EU/1/18/1334 20181122 |
| 2603514 | 132019000000051 | Italy | ⤷ Start Trial | PRODUCT NAME: COMBINAZIONE DI VABORBACTAM E/O UN SUO SALE E/O UN SUO IDRATO, E MEROPENEM, E/O UN SUO SALE E/O UN SUO IDRATO, IN PARTICOLARE MEROPENEM TRIIDRATO(VABOMERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1334, 20181122 |
| 0720599 | 300689 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 2603514 | 1990017-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF VABORBACTAM AND/OR SALT OR HYDRATE THEREOF, AND MEROPENEM AND/OR A SALT HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE.; REG. NO/DATE: EU/1/18/1334 20181122 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
